SAGE Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Good morning, everyone. Welcome to our Piper Healthcare Conference here in New York City. It is day three. My name is Yas Rahimi. I'm a senior biotech analyst here at Piper Sandler. Thrilled to be featuring a great company going after amazing causes, and who've been a pioneer in the space. Sage Therapeutics team, wonderful to have you here from Boston.
We have lots of questions prepared for you. So maybe before we get started, I'm going to let you come and give me a quick overview on where is Sage's key priorities in 2023, as the year is coming to an end.
Great. Sure. Thanks, Yas, for having us. And it's great to be back in the city. It's really hustling and bustling out there. So Sage is in the area of brain health. For those of you who aren't familiar with Sage, we've been at it for some time now, made a tremendous amount of progress. So I'll give you the highlights and it's really across three franchise areas. Our depression franchise right now is zuranolone is in the spotlight.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |